Zim Laboratories (NSE:ZIMLAB) Beneish M-Score: -2.80 (As of Jun. 26, 2026)


NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
76 GF Score
Price ₹124.90
GF Value ₹102.88
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories Beneish M-Score?

Zim Laboratories NSE:ZIMLAB -2.32% 76 Beneish M-Score is -2.80 as of Jun. 26, 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.88 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 911 Drug Manufacturers companies, Zim Laboratories ranks better than 74.75% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.8 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zim Laboratories's Beneish M-Score or its related term are showing as below:

NSE:ZIMLAB' s Beneish M-Score Range Over the Past 10 Years
Min: -2.94   Med: -2.78   Max: -2.4
Current: -2.8

During the past 12 years, the highest Beneish M-Score of Zim Laboratories was -2.40. The lowest was -2.94. And the median was -2.78.


Zim Laboratories Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Beneish M-Score Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.94 -2.40 -2.40 -2.80 -2.80

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.80 0.00 0.00 0.00 -2.80

NSE:ZIMLAB vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's Beneish M-Score falls into.


NSE:ZIMLAB
76GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zim Laboratories for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0278+0.528 * 0.9945+0.404 * 1.0984+0.892 * 0.9922+0.115 * 1.0641
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0564+4.679 * -0.08101-0.327 * 0.9766
=-2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹1,091 Mil.
Revenue was ₹3,600 Mil.
Gross Profit was ₹1,937 Mil.
Total Current Assets was ₹2,758 Mil.
Total Assets was ₹5,394 Mil.
Property, Plant and Equipment(Net PPE) was ₹2,152 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹200 Mil.
Selling, General, & Admin. Expense(SGA) was ₹398 Mil.
Total Current Liabilities was ₹1,904 Mil.
Long-Term Debt & Capital Lease Obligation was ₹424 Mil.
Net Income was ₹58 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹495 Mil.
Total Receivables was ₹1,070 Mil.
Revenue was ₹3,629 Mil.
Gross Profit was ₹1,941 Mil.
Total Current Assets was ₹2,313 Mil.
Total Assets was ₹4,723 Mil.
Property, Plant and Equipment(Net PPE) was ₹2,024 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹201 Mil.
Selling, General, & Admin. Expense(SGA) was ₹380 Mil.
Total Current Liabilities was ₹1,664 Mil.
Long-Term Debt & Capital Lease Obligation was ₹424 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1091.094 / 3600.419) / (1069.962 / 3628.868)
=0.303046 / 0.294847
=1.0278

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1941.471 / 3628.868) / (1936.913 / 3600.419)
=0.535007 / 0.537969
=0.9945

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2758.085 + 2151.925) / 5393.871) / (1 - (2313.074 + 2023.983) / 4722.743)
=0.089706 / 0.081666
=1.0984

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3600.419 / 3628.868
=0.9922

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(201.134 / (201.134 + 2023.983)) / (199.78 / (199.78 + 2151.925))
=0.090393 / 0.084951
=1.0641

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(398.428 / 3600.419) / (380.12 / 3628.868)
=0.110662 / 0.104749
=1.0564

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((424.203 + 1903.924) / 5393.871) / ((423.707 + 1663.646) / 4722.743)
=0.431625 / 0.441979
=0.9766

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(58.381 - 0 - 495.341) / 5393.871
=-0.08101

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zim Laboratories has a M-score of -2.80 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.80 mean?
Zim Laboratories (NSE:ZIMLAB) has a Beneish M-Score of -2.80 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Zim Laboratories and its competitors. According to the industry distribution chart, Zim Laboratories ranks #230 out of 911 companies in the Drug Manufacturers industry, placing it in the top 25.2%.
Is Zim Laboratories' Beneish M-Score too high?
Zim Laboratories' current Beneish M-Score is -2.80. Based on the distribution chart, Zim Laboratories ranks #230 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #230 out of 911 companies for Beneish M-Score. This puts Zim Laboratories in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Zim Laboratories and its competitors. Zim Laboratories's current Beneish M-Score is -2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.88, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current Beneish M-Score is -2.80. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Beneish M-Score is -2.80 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.88. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • Beneish M-Score: -2.80
  • GF Value™: ₹102.88 vs. price of ₹124.90 (21.4% above fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score

Get the complete analysis for NSE:ZIMLAB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹124.90
Price
₹102.88
GF Value